pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·3h ago·1 min read
save

Former CDC investigator warns that gaps in public-health readiness leave the U.S. vulnerable to future biothreats

Sep 26, 2026·read at STAT ↗Neutral

Daniel Jernigan, a former CDC scientist who helped investigate the 2001 anthrax mailings, reflects on the lessons learned two and a half decades later.

The anthrax letters, sent from New Jersey to media outlets and congressional offices, caused 22 infections and five deaths, sparked nationwide fear, and cost billions of dollars in response and recovery efforts.

Jernigan argues that the attacks showed how easily the postal system can be weaponized and that modern alert and mitigation systems still have significant gaps.

He calls for renewed investment in public‑health infrastructure and rapid response capabilities to protect against both intentional and accidental biothreats.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: I worked on the CDC investigation of the anthrax letters. 25 years later, are we ready for the next biothreat?”

read at STAT ↗
1,461 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING3PATH
topics
Infectious Disease3Vaccines2CardiologyDermatology

related stories

  • 3d agoNovo workforce down 13,000BioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Aug 27FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adultsfda press
  • Dec 22Fierce Biotech Fundraising Tracker '26: Sling reels in $123M; Circle gathers $92.5MFierce Biotech
  • Sep 17Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trialBioSpace